S'abonner

Diagnostic accuracy and safety of 16?-[18F]fluoro-17?-oestradiol PET-CT for the assessment of oestrogen receptor status in recurrent or metastatic lesions in patients with breast cancer: a prospective cohort study - 03/04/19

Doi : 10.1016/S1470-2045(18)30936-7 
Sun Young Chae, MD a, , Sei Hyun Ahn, ProfMD b, , Sung-Bae Kim, ProfMD c, , Sangwon Han, MD a, Suk Hyun Lee, MD a, Seung Jun Oh, ProfPhD a, Sang Ju Lee, PhD a, Hee Jeong Kim, MD b, Beom Seok Ko, MD b, Jong Won Lee, MD b, Byung Ho Son, ProfMD b, Jisun Kim, MD b, Jin-Hee Ahn, ProfMD c, Kyung Hae Jung, ProfMD c, Jeong Eun Kim, MD c, Seog-Young Kim, PhD d, Woo Jung Choi, MD e, Hee Jung Shin, MD d, Gyungyub Gong, ProfMD f, Hyo Sang Lee, MD h, Jung Bok Lee, PhD g, Dae Hyuk Moon, ProfMD a,
a Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea 
b Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea 
c Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea 
d Convergence Medicine Research Center, Department of Convergence Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea 
e Department of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea 
f Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea 
g Department of Clinical Epidemiology and Biostatistics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea 
h Department of Nuclear Medicine, Gangneung Asan Hospital, University of Ulsan College of Medicine, Gangneung, South Korea 

* Correspondence to: Prof Dae Hyuk Moon, Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul 05505, South Korea Department of Nuclear Medicine Asan Medical Center University of Ulsan College of Medicine Seoul 05505 South Korea

Summary

Background

A biopsy of first recurrence or metastatic disease is recommended to re-evaluate oestrogen receptor status in patients with breast cancer and to select appropriate treatment. However, retesting for oestrogen receptor status with rebiopsy is not always feasible, depending on lesion location and the risk associated with biopsy, and in these cases clinicians continue to treat patients according to the oestrogen receptor status of the primary tumour. Consequently suboptimal therapy might be offered to these patients. We assessed the diagnostic accuracy and safety of 16α-[18F]fluoro-17β-oestradiol (18F-FES) PET-CT to assess oestrogen receptor status in patients with recurrent or metastatic breast cancer.

Methods

We did a prospective cohort study at the Asan Medical Center, Seoul, South Korea. Eligible patients had breast cancer, with first recurrence or metastatic disease at presentation, were 19 years or older, and had an Eastern Cooperative Oncology Group performance status of 0–2. The primary objective was to show the agreement between qualitative 18F-FES PET-CT interpretation and the results of oestrogen receptor expression by immunohistochemical assay, a non-reference standard test. Whole-body 18F-FES PET-CT imaging was done after intravenous injection of 111–222 MBq of 18F-FES, with dosing primarily determined by radiation dosimetry analysis. 18F-FES uptake above background intensity was interpreted as positive. Efficacy was assessed in all patients with histologically confirmed recurrent or metastatic breast cancer who received 18F-FES and had PET-CT images available (intention-to-diagnose analysis), and safety was assessed in all patients who received 18F-FES. This study is registered with ClinicalTrials.gov, number NCT01986569.

Findings

Between Nov 27, 2013, and Nov 10, 2016, 93 patients were enrolled. Of the 85 patients included in the efficacy analysis, 47 (55%) were oestrogen receptor-positive and 38 (45%) were oestrogen receptor-negative. Positive status percent agreement between the 18F-FES PET-CT results and oestrogen receptor status by immunohistochemical assay was 76·6% (95% CI 62·0–87·7) and the negative status percent agreement was 100·0% (90·8–100·0). Patients who were oestrogen receptor-positive and had a positive 18F-FES PET-CT result had a significantly higher progesterone receptor expression than those who were oestrogen receptor-positive and had a negative 18F-FES PET-CT result (23 [68%] of 34 patients vs 0 of 11 patients; p<0·0001). The most common adverse event was procedural pain in nine (10%) of 90 patients injected with 18F-FES. No adverse events were related to the study drug except injection site pain in one (1%) patient. No serious adverse events were recorded.

Interpretation

The high negative percent agreement between 18F-FES PET-CT and oestrogen receptor status by immunohistochemical assay in this cohort suggests that positive 18F-FES uptake by recurrent or metastatic oestrogen receptor-positive breast cancer lesions could be an alternative to oestrogen receptor assays in this setting. Staging assessment should include 18F-FES PET-CT when retesting oestrogen receptor status is not feasible.

Funding

Asan Institute for Life Sciences, Ministry of Health and Welfare, South Korea.

Le texte complet de cet article est disponible en PDF.

Plan


© 2019  Elsevier Ltd. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 20 - N° 4

P. 546-555 - avril 2019 Retour au numéro
Article précédent Article précédent
  • Risk of subsequent primary neoplasms in survivors of adolescent and young adult cancer (Teenage and Young Adult Cancer Survivor Study): a population-based, cohort study
  • Chloe J Bright, Raoul C Reulen, David L Winter, Daniel P Stark, Martin G McCabe, Angela B Edgar, Clare Frobisher, Michael M Hawkins
| Article suivant Article suivant
  • Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial
  • Bertrand Tombal, Fred Saad, David Penson, Maha Hussain, Cora N Sternberg, Robert Morlock, Krishnan Ramaswamy, Cristina Ivanescu, Gerhardt Attard

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.